AUS
NZ
UK
CA
USA
IND
Since the start of 2024, CSL Ltd (ASX:CSL) has seen its share price rise by 6.0%. This growth has sparked significant interest among investors. Here’s a detailed look at why CSL shares are attracting attention and what makes this biotechnology company stand out.
Understanding CSL Ltd
CSL is a global biotechnology firm renowned for developing and delivering innovative medicines that play a crucial role in saving lives, safeguarding public health, and aiding individuals with serious medical conditions. The company operates through three main divisions:
- CSL Behring: Acquired in 2004, CSL Behring specializes in the manufacturing and distribution of blood plasma products. This division focuses on delivering treatments for rare and serious conditions.
- CSL Seqirus: Formed from the rebranding of BioCSL and the acquisition of Novartis' flu business in 2015, CSL Seqirus produces flu vaccines and offers pandemic-related services to governments.
- CSL Vifor: This division, acquired in recent years, is dedicated to creating products for managing iron deficiency and renal (kidney) care.
CSL has earned a reputation as a reliable company and consistent dividend payer in the Australian market. For many investors, CSL represents a way to gain exposure to the rising healthcare costs sector indirectly.
The Case for Healthcare Investments
The healthcare sector, represented by the S&P/ASX 200 Healthcare Index (ASX:XHJ), has delivered an annual return of 4.74% over the past five years, outperforming the broader ASX sectors average of 4.25% during the same period. Here are some reasons why healthcare companies like CSL are often favored:
- Consistent Revenue: Healthcare is categorized as essential spending. This means that even during economic downturns, spending on healthcare is one of the last expenses people are likely to cut. Healthcare companies offer essential services that remain relatively unaffected by commodity price fluctuations or seasonal demand, making their revenue more stable. Historically, the healthcare sector has performed well during economic recessions, including the Global Financial Crisis (GFC).
- Growth Potential: The US, accounting for over 40% of global healthcare expenditure, is projected to see a 7% annual increase in healthcare profits from 2022 to 2027, reaching approximately US$819 billion. Within the healthcare sector, certain areas show exceptional growth potential. For instance, companies involved in IT and data solutions, as well as 'software-as-a-service' (SaaS), are expected to experience annual growth rates exceeding 15% from 2024 to 2030.
- Ethical Investing: A recent survey by Morgan Stanley indicated that over half of investors are planning to increase their allocation to sustainable investments in 2024. The growing interest in ethical or sustainable investing suggests that sectors like healthcare, which provide vital public services, could be well-positioned to benefit from this trend.
For those examining CSL Ltd’s share price, dividend yield is a useful metric to consider. The dividend yield represents the cash flow received by shareholders but can fluctuate from year to year. Currently, CSL shares offer a dividend yield of around 1.29%, which is below its 5-year average of 1.50%. This indicates that CSL shares are trading below their historical average dividend yield, potentially signaling an attractive entry point for those interested in dividend income.
CSL Ltd's recent share price performance reflects strong investor interest, driven by its solid financial performance, the stability and growth potential of the healthcare sector, and the increasing appeal of ethical investing. With its consistent dividend payouts and a strong reputation in the biotechnology industry, CSL continues to be a noteworthy option for those looking to invest in the healthcare sector.
